Related Experiment Videos
Method for studying drug-warfarin interactions
M Grind1, M Murphy, S Warrington
1Astra Hässle AB, Mölndal, Sweden.
Clinical Pharmacology and Therapeutics
|October 1, 1993
Summary
Extended-release felodipine did not significantly affect warfarin pharmacokinetics or pharmacodynamics in healthy men. This study suggests felodipine is safe to co-administer with warfarin, impacting anticoagulation therapy.
Area of Science:
- Pharmacology
- Drug Interactions
- Clinical Pharmacology
Background:
- Warfarin is a widely used anticoagulant.
- Understanding drug interactions is crucial for safe warfarin therapy.
- Extended-release felodipine is a calcium channel blocker used for hypertension.
Purpose of the Study:
- To investigate the potential pharmacokinetic and pharmacodynamic interactions between extended-release felodipine and warfarin.
- To assess the safety and efficacy of co-administering these medications.
Main Methods:
- A double-blind, placebo-controlled, crossover study was conducted in 12 healthy male subjects.
- Warfarin dosage was stabilized to achieve subtherapeutic anticoagulation.
- Subjects received either 10 mg extended-release felodipine or placebo daily for two weeks, with subsequent crossover.
Main Results:
- No significant differences in the pharmacokinetics of R- and S-warfarin were observed between felodipine and placebo treatment periods.
- Warfarin dose requirements remained stable, indicating no clinically important impact on anticoagulation.
- The international normalized ratio (INR) was consistently maintained across both treatment arms.
Conclusions:
- Extended-release felodipine does not appear to significantly alter warfarin pharmacokinetics or pharmacodynamics.
- The study design is suitable for evaluating other drug interactions with warfarin.
- This finding supports the potential for safe co-administration of extended-release felodipine and warfarin.